{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:48:58Z","timestamp":1791946138743,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["31003A_166613"],"award-info":[{"award-number":["31003A_166613"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_185297"],"award-info":[{"award-number":["310030_185297"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-3655-02-2015"],"award-info":[{"award-number":["KFS-3655-02-2015"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-4462-02-2018"],"award-info":[{"award-number":["KFS-4462-02-2018"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Interleukin-1\u03b2 (IL-1\u03b2) is a master regulator of inflammation. Increased activity of IL-1\u03b2 has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs). Here we show that IL-1\u03b2 serum levels and expression of IL-1 receptors on hematopoietic progenitors and stem cells correlate with\n                    <jats:italic>JAK2<\/jats:italic>\n                    -V617F mutant allele fraction in peripheral blood of patients with MPN. We show that the source of IL-1\u03b2 overproduction in a mouse model of MPN are\n                    <jats:italic>JAK2<\/jats:italic>\n                    -V617F expressing hematopoietic cells. Knockout of\n                    <jats:italic>IL-1\u03b2<\/jats:italic>\n                    in hematopoietic cells of\n                    <jats:italic>JAK2<\/jats:italic>\n                    -V617F mice reduces inflammatory cytokines, prevents damage to nestin-positive niche cells and reduces megakaryopoiesis, resulting in decrease of myelofibrosis and osteosclerosis. Inhibition of IL-1\u03b2 in\n                    <jats:italic>JAK2<\/jats:italic>\n                    -V617F mutant mice by anti-IL-1\u03b2 antibody also reduces myelofibrosis and osteosclerosis and shows additive effects with ruxolitinib. These results suggest that inhibition of IL-1\u03b2 with anti-IL-1\u03b2 antibody alone or in combination with ruxolitinib could have beneficial effects on the clinical course in patients with myelofibrosis.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-32927-4","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T06:23:33Z","timestamp":1663050213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm"],"prefix":"10.1038","volume":"13","author":[{"given":"Shivam","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Grockowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Luque Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric B.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hao-Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Mild-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dirnhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-9721","authenticated-orcid":false,"given":"Christopher J.","family":"Farady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00f3n","family":"M\u00e9ndez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-9496","authenticated-orcid":false,"given":"Radek C.","family":"Skoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"32927_CR1","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","volume":"112","author":"RL Levine","year":"2008","unstructured":"Levine, R. L. & Gilliland, D. G. Myeloproliferative disorders. Blood 112, 2190\u20132198 (2008).","journal-title":"Blood"},{"key":"32927_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker, W. & Kralovics, R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129, 667\u2013679 (2017).","journal-title":"Blood"},{"key":"32927_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/bjh.16576","volume":"191","author":"N Gangat","year":"2020","unstructured":"Gangat, N. & Tefferi, A. Myelofibrosis biology and contemporary management. Br. J. Haematol. 191, 152\u2013170 (2020).","journal-title":"Br. J. Haematol."},{"key":"32927_CR4","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)\u22128, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"32927_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya, R. et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am. J. Hematol. 87, 1003\u20131005 (2012).","journal-title":"Am. J. Hematol."},{"key":"32927_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe, M. et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 5, 316\u2013331 (2015).","journal-title":"Cancer Discov."},{"key":"32927_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe, M. et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33, 785\u2013787 (2018).","journal-title":"Cancer Cell"},{"key":"32927_CR8","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood.2019004095","volume":"136","author":"HFE Gleitz","year":"2020","unstructured":"Gleitz, H. F. E. et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood 136, 2051\u20132064 (2020).","journal-title":"Blood"},{"key":"32927_CR9","doi-asserted-by":"crossref","unstructured":"Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. Sci. Signal. 3, cm1 (2010).","DOI":"10.1126\/scisignal.3105cm1"},{"key":"32927_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327 (2018).","journal-title":"Immunol. Rev."},{"key":"32927_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz, L. et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512, 78\u201381 (2014).","journal-title":"Nature"},{"key":"32927_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb3346","volume":"18","author":"EM Pietras","year":"2016","unstructured":"Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607\u2013618 (2016).","journal-title":"Nat. Cell Biol."},{"key":"32927_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1074\/mcp.M600455-MCP200","volume":"6","author":"C Brikos","year":"2007","unstructured":"Brikos, C., Wait, R., Begum, S., O\u2019Neill, L. A. & Saklatvala, J. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol. Cell. Proteom. 6, 1551\u20131559 (2007).","journal-title":"Mol. Cell. Proteom."},{"key":"32927_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003\u20131018 (2013).","journal-title":"Immunity"},{"key":"32927_CR15","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3389\/fimmu.2019.01412","volume":"10","author":"JK Fields","year":"2019","unstructured":"Fields, J. K., Gunther, S. & Sundberg, E. J. Structural basis of IL-1 family cytokine signaling. Front Immunol. 10, 1412 (2019).","journal-title":"Front Immunol."},{"key":"32927_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New Engl. J. Med. 363, 1117\u20131127 (2010).","journal-title":"New Engl. J. Med."},{"key":"32927_CR17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","volume":"99","author":"CN Harrison","year":"2020","unstructured":"Harrison, C. N., Schaap, N. & Mesa, R. A. Management of myelofibrosis after ruxolitinib failure. Ann. Hematol. 99, 1177\u20131191 (2020).","journal-title":"Ann. Hematol."},{"key":"32927_CR18","doi-asserted-by":"publisher","unstructured":"Rahman, M. F. et al. Interleukin-1 contributes to clonal expansion and progression of JAK2V617F-induced myeloproliferative neoplasms. https:\/\/doi.org\/10.1038\/s41467-022-32928-3 (2022).","DOI":"10.1038\/s41467-022-32928-3"},{"key":"32927_CR19","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","volume":"124","author":"R Norfo","year":"2014","unstructured":"Norfo, R. et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis. Blood 124, e21\u2013e32 (2014).","journal-title":"Blood"},{"key":"32927_CR20","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt, R. et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931\u20133940 (2008).","journal-title":"Blood"},{"key":"32927_CR21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1182\/blood-2012-03-415646","volume":"121","author":"L Kubovcakova","year":"2013","unstructured":"Kubovcakova, L. et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 121, 1188\u20131199 (2013).","journal-title":"Blood"},{"key":"32927_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/1074-7613(95)90154-X","volume":"3","author":"H Zheng","year":"1995","unstructured":"Zheng, H. et al. Resistance to fever induction and impaired acute-phase response in interleukin-1-beta-deficient mice. Immunity 3, 9\u201319 (1995).","journal-title":"Immunity"},{"key":"32927_CR23","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","volume":"139","author":"CA Dinarello","year":"1987","unstructured":"Dinarello, C. A. et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139, 1902\u20131910 (1987).","journal-title":"J. Immunol."},{"key":"32927_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cne.10964","volume":"469","author":"JL Mignone","year":"2004","unstructured":"Mignone, J. L., Kukekov, V., Chiang, A. S., Steindler, D. & Enikolopov, G. Neural stem and progenitor cells in nestin-GFP transgenic mice. J. Comp. Neurol. 469, 311\u2013324 (2004).","journal-title":"J. Comp. Neurol."},{"key":"32927_CR25","doi-asserted-by":"crossref","unstructured":"Allain-Maillet, S. et al. Anti-glucosylsphingosine autoimmunity, JAK2V617F-dependent interleukin-1beta and JAK2V617F-independent cytokines in myeloproliferative neoplasms. Cancers 12, 2446 (2020).","DOI":"10.3390\/cancers12092446"},{"key":"32927_CR26","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl Acad. Sci. USA 107, 16280\u201316285 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32927_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120, 1290\u20131298 (2012).","journal-title":"Blood"},{"key":"32927_CR28","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H Agerstam","year":"2016","unstructured":"Agerstam, H. et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 128, 2683\u20132693 (2016).","journal-title":"Blood"},{"key":"32927_CR29","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey, A. et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"32927_CR30","doi-asserted-by":"publisher","first-page":"11052","DOI":"10.1016\/S0021-9258(18)37917-1","volume":"263","author":"PD Bonin","year":"1988","unstructured":"Bonin, P. D. & Singh, J. P. Modulation of interleukin-1 receptor expression and interleukin-1 response in fibroblasts by platelet-derived growth factor. J. Biol. Chem. 263, 11052\u201311055 (1988).","journal-title":"J. Biol. Chem."},{"key":"32927_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1172\/JCI113719","volume":"82","author":"T Akahoshi","year":"1988","unstructured":"Akahoshi, T., Oppenheim, J. J. & Matsushima, K. Interleukin 1 stimulates its own receptor expression on human fibroblasts through the endogenous production of prostaglandin(s). J. Clin. Invest. 82, 1219\u20131224 (1988).","journal-title":"J. Clin. Invest."},{"key":"32927_CR32","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","volume":"90","author":"JL Villeval","year":"1997","unstructured":"Villeval, J. L. et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90, 4369\u20134383 (1997).","journal-title":"Blood"},{"key":"32927_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea, S. O. et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110, 986\u2013993 (2007).","journal-title":"Blood"},{"key":"32927_CR34","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood.V76.12.2493.2493","volume":"76","author":"H Kimura","year":"1990","unstructured":"Kimura, H. et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood 76, 2493\u20132500 (1990).","journal-title":"Blood"},{"key":"32927_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jcp.1041500109","volume":"150","author":"RT Means Jr.","year":"1992","unstructured":"Means, R. T. Jr., Dessypris, E. N. & Krantz, S. B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J. Cell Physiol. 150, 59\u201364 (1992).","journal-title":"J. Cell Physiol."},{"key":"32927_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.1365-2141.1999.01569.x","volume":"106","author":"S van den Oudenrijn","year":"1999","unstructured":"van den Oudenrijn, S., de Haas, M., Calafat, J., van der Schoot, C. E., & von dem Borne, A. E. A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes. Br. J. Haematol. 106, 553\u2013563 (1999).","journal-title":"Br. J. Haematol."},{"key":"32927_CR37","first-page":"371","volume":"111","author":"M Yang","year":"2000","unstructured":"Yang, M. et al. Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression. Br. J. Haematol. 111, 371\u2013380 (2000).","journal-title":"Br. J. Haematol."},{"key":"32927_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/ATVBAHA.113.302700","volume":"34","author":"LM Beaulieu","year":"2014","unstructured":"Beaulieu, L. M. et al. Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler. Thromb. Vasc. Biol. 34, 552\u2013564 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"32927_CR39","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui, H. et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100, 3495\u20133503 (2002).","journal-title":"Blood"},{"key":"32927_CR40","doi-asserted-by":"crossref","unstructured":"Drexler, B. et al. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33\/14. Haematologica 104, 710\u2013716 (2018).","DOI":"10.3324\/haematol.2018.200014"},{"key":"32927_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cyto.2008.07.004","volume":"44","author":"O Osborn","year":"2008","unstructured":"Osborn, O. et al. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44, 141\u2013148 (2008).","journal-title":"Cytokine"},{"key":"32927_CR42","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","volume":"24","author":"D Gomez","year":"2018","unstructured":"Gomez, D. et al. Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat. Med. 24, 1418\u20131429 (2018).","journal-title":"Nat. Med."},{"key":"32927_CR43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.119.044320","volume":"141","author":"F Potus","year":"2020","unstructured":"Potus, F. et al. Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension. Circulation 141, 1986\u20132000 (2020).","journal-title":"Circulation"},{"key":"32927_CR44","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.1073\/pnas.0402800101","volume":"101","author":"JK Lee","year":"2004","unstructured":"Lee, J. K. et al. Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl Acad. Sci. USA 101, 8815\u20138820 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32927_CR45","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","volume":"35","author":"S Brkic","year":"2021","unstructured":"Brkic, S. et al. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia 35, 2875\u20132884 (2021).","journal-title":"Leukemia"},{"key":"32927_CR46","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","volume":"21","author":"QJ Wen","year":"2015","unstructured":"Wen, Q. J. et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat. Med 21, 1473\u20131480 (2015).","journal-title":"Nat. Med"},{"key":"32927_CR47","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"32927_CR48","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics, R. et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108, 1377\u20131380 (2006).","journal-title":"Blood"},{"key":"32927_CR49","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1895","volume":"214","author":"BC Schaefer","year":"2001","unstructured":"Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P. & Kedl, R. M. Observation of antigen-dependent CD8+ T-cell\/ dendritic cell interactions in vivo. Cell Immunol. 214, 110\u2013122 (2001).","journal-title":"Cell Immunol."},{"key":"32927_CR50","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1084\/jem.187.9.1463","volume":"187","author":"R Horai","year":"1998","unstructured":"Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha\/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med 187, 1463\u20131475 (1998).","journal-title":"J. Exp. Med"},{"key":"32927_CR51","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1182\/blood.2019000162","volume":"134","author":"TN Rao","year":"2019","unstructured":"Rao, T. N. et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood 134, 1832\u20131846 (2019).","journal-title":"Blood"},{"key":"32927_CR52","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2020005563","volume":"137","author":"TN Rao","year":"2021","unstructured":"Rao, T. N. et al. JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood 137, 2139\u20132151 (2021).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32927-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T17:30:17Z","timestamp":1676741417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32927-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32927"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32927-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.C.S. has consulted for and received honoraria from Novartis and Celgene\/BMS, he is a scientific advisor\/SAB member and has equity in Ajax Therapeutics; N.H. owns stocks in the company Cantargia; C.J.F. is a full-time employee of Novartis Pharma AG. The inhibitor studies were carried out in the laboratory of R.C.S. with inhibitors provided by Novartis. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5346"}}